Lamisil Oral Granules Side Effects
Please note - some side effects for Lamisil Oral Granules may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
Side Effects of Lamisil Oral Granules - for the Consumer
Lamisil Oral Granules
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Lamisil Oral Granules:
Seek medical attention right away if any of these SEVERE side effects occur when using Lamisil Oral Granules:
Cough; diarrhea; headache; indigestion; mild stomach pain; nausea; symptoms of upper respiratory tract infection (eg, mild sore throat, runny or stuffy nose, sneezing); vomiting.
Severe allergic reactions (rash; hives; itching; difficulty breathing or swallowing; tightness in the chest; swelling of the mouth, face, lips, throat, or tongue; unusual hoarseness); mental or mood changes (eg, depression, restlessness, sadness, worthlessness); mouth sores; new or worsening symptoms of lupus (eg, butterfly-shaped rash on the face, joint pain, seizures, skin color changes, unusual sensitivity to the sun); red, blistered, peeling, or swollen skin; severe muscle pain or tenderness; sleep problems; symptoms of infection (eg, fever, chills, persistent sore throat); symptoms of liver problems (eg, dark urine; loss of appetite, pale stools; unexplained, persistent nausea or stomach pain; vomiting; yellowing of the skin or eyes); unusual bruising or bleeding; unusual tiredness or weakness; vision changes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.Top
Side Effects by Body System - for Healthcare Professionals
Applies to: oral granule; oral tablet
In general, terbinafine side effects have been mild and transient. However, the drug has been associated with serious life threatening events such as hepatic failure, anaphylaxis, and severe neutropenia.
Gastrointestinal side effects have included diarrhea (5.6%), dyspepsia (4.3%), taste disturbance (2.8%), nausea (2.6%), abdominal pain (2.4%), and flatulence (2.2%). Mild to moderate gastrointestinal discomfort, gastritis, gastric fullness, nausea and vomiting, taste alteration (rarely accompanied by discoloration of the tongue and/or disturbance in the sense of smell), hypogeusia, ageusia, and a metallic taste have been reported. At least one case of a drug reaction with eosinophilia and systemic symptoms associated with severe sialadenitis induced by terbinafine has been reported. Vomiting and pancreatitis have been reported during postmarketing experience.
Patients with hiatal hernia or gastric duodenal ulcer disease may be more likely to experience mild to moderate gastrointestinal discomfort, diarrhea, dyspepsia, nausea and vomiting, gastritis, gastric fullness, and flatulence.
Taste disturbances were typically noticed 5 to 8 weeks after starting therapy and returned to normal 2 to 5 weeks after stopping the medication. The taste alteration has been rarely accompanied by a discoloration of the tongue and/or a disturbance in the sense of smell.
An 80-year-old female experienced a drug reaction with eosinophilia and systemic symptoms (DRESS) secondary to severe sialadenitis coincident with terbinafine therapy. The patient was admitted with a generalized pruriginous eruption. She presented with erythematous and edematous widespread confluent plaques, with a scaly annular border. She had initiated terbinafine therapy 14 days before onset of the generalized rash, for a nonspecific squamous plaque of the trunk. DRESS induced by terbinafine was diagnosed and terbinafine intake was discontinued. Topical therapy was started with 0.5% clobetasol propionate cream applied to the whole body. The rash progressively improved and blood eosinophilia decreased.
An 81-year-old male who had been treated with topical antifungal agents for tinea pedis started oral terbinafine 125 mg daily as the lesions did not respond to topical therapy. He was not taking any other medications and had no history of skin disease. No other skin lesions were observed at that time. Two weeks later, he developed erythematous and pustular lesions on his fingers and toes, and an erythematous macular eruption on the limbs. Oral terbinafine therapy was discontinued, but the eruptions continued to worsen. Histopathology of a punch biopsy from his toe showed intraepidermal sterile pustules containing neutrophils, so-called Kogoj's spongiform pustules. He was then diagnosed with having acrodermatitis continua of Hallopeau and was treated with corticosteroids therapy.
A 68-year-old male experienced acute generalized exanthematous pustulosis coincident with terbinafine therapy. He presented with a symmetrical maculopapular eruption on both lower anterior legs. Within two days, the rash generalized with facial involvement. He developed the rash 20 days after initiating oral terbinafine for onychomycosis. After withdrawal of terbinafine, the exanthema abated within 10 days under topical therapy with corticosteroids.
Dermatologic side effects have included rash (5.6%), pruritus (2.8%), urticaria (1.1%), and eczema. Reversible alopecia areata of the scalp and pustular psoriasis have been rarely reported. Erythema multiforme and at least one case of acrodermatitis continua of Hallopeau have been reported. Serious skin reactions (e.g., Stevens-Johnson syndrome and toxic epidermal necrolysis), psoriasiform eruptions or exacerbation of psoriasis, acute generalized exanthematous pustulosis, hair loss, photosensitivity reactions, and precipitation and exacerbation of cutaneous and systemic lupus erythematosus have been reported during postmarketing experience.
Nervous system side effects have included headache (12.9%), dizziness, and insomnia. Taste disturbance (including taste loss), smell disturbance (including loss of smell), tinnitus, hearing impairment, and vertigo have been reported during postmarketing experience. Some cases of taste disturbance were severe enough to cause decreased food intake, weight loss, and depressive symptoms.
A 57-year-old male with chronic hepatitis B virus (HBV) infection developed terbinafine-induced acute autoimmune hepatitis coincident with terbinafine therapy. He was given 250 mg of terbinafine once daily over a 12-week period for dermatophyte toenail onychomycosis. He developed the adverse event just prior to completing the course of therapy. He was not taking any other drugs or herbal supplements, did not drink alcohol, and did not appear to suffer a flare of HBV infection. Liver function studies began to normalize 6 weeks after terbinafine was discontinued.
Hepatic side effects have included liver enzyme abnormalities (greater than or equal to 2 times ULN; 3.3%). Transient elevations in serum liver enzymes, the development of idiosyncratic and symptomatic hepatobiliary dysfunction, and at least one case of terbinafine-induced autoimmune hepatitis have been reported. Idiosyncratic and symptomatic hepatic injury and rare cases of liver failure (some leading to death or liver transplantation) have been reported during postmarketing experience.
Hematologic side effects have included leukopenia and lymphopenia. Pancytopenia, anemia, thrombocytopenia, agranulocytosis, and severe neutropenia have been reported during postmarketing experience.
Ocular side effects have included visual disturbance (1.1%). Changes in the ocular lens and retina have been reported; however, the clinical significance is unknown. Dyschromatopsia, whereby the patient reported a greenish hue in her vision, and photopsia have occurred in a patient after three weeks of therapy. This problem resolved within 1 week of discontinuing the drug. Reduced visual acuity and visual field defect have been reported during postmarketing experience.
Metabolic side effects have included hypoglycemia and hypotriglyceridemia.
Genitourinary side effects have included transient erectile dysfunction in male patients (extremely rare).
Renal side effects have been uncommonly reported. These have included a case of renal function test impairment and rare cases of hematuria.
Hypersensitivity side effects have included rare cases of anaphylaxis and hypersensitivity reactions. Angioedema, allergic reactions (including anaphylaxis), and serum sickness-like reaction have been reported during postmarketing experience.
Musculoskeletal side effects have included arthralgia, myalgia, rhabdomyolysis, and increased blood creatine phosphokinase during postmarketing experience.
Cardiovascular side effects have included vasculitis during postmarketing experience.
Other side effects have included malaise, fatigue, influenza-like illness, and pyrexia during postmarketing experience.
Psychiatric side effects have included depressive symptoms (independent of taste disturbance) during postmarketing experience.Top
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.